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ABSTRACT
Reduced-intensity conditioning (RIC) regimens have been increasingly used for allogeneic hematopoietic stem
cell transplantation (HSCT) in follicular lymphoma (FL). We compared traditional myeloablative conditioning
regimens to RIC in FL. Outcomes of HLA-identical sibling HSCT for FL in 208 recipients reported to the Cen-
ter for International Blood and Marrow Transplant Research (CIBMTR) between 1997 and 2002 were studied.
Conditioning regimens were categorized as myeloablative (N5 120) or RIC (N5 88). Use of RIC regimens in-
creased from\10% of transplants in 1997 to.80% in 2002 signaling a major shift in practice. Patients receiving
RIC were older and had a longer interval from diagnosis to transplant. These differences did not correlate with
outcomes. Median follow-up of survivors was 50 months (4-96 months) after myeloablative conditioning versus
35 months (4-82 months) after RIC (P\ .001). At 3 years, overall survival (OS) for the myeloablative and RIC
cohorts were 71 (63%-79%) and 62 (51%-72%; P 5 .15) and progression free survival (PFS), 67 (58%-75%)
and 55 (44%-65%; P 5 .07), respectively. Lower Karnofsky performance score (KPS) and resistance to chemo-
therapy were associated with higher treatment-relatedmortality (TRM) and lower OS and PFS. Onmultivariate
analysis, an increased risk of lymphoma progression after RIC was observed (relative risk 5 2.97, P 5 .04). RIC
has become the de facto standard in allogeneic HSCT for FL, and appears to result in similar long-term out-
comes. Although disease-free survival (DPS) is similar compared to myeloablative conditioning, an increased
risk of late disease progression after RIC is concerning.
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Conventional chemotherapy, for follicular lym-
phoma (FL), although much improved, is not curative
[1]. Allogeneic hematopoietic stem cell transplantation236(HSCT) has a low recurrence rate and can sometimes
cure FL, but traditional myeloablative conditioning
regimens are associated with substantial treatment-
related mortality (TRM), especially in older persons
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resistant lymphoma [2,3].
Reduced-intensity conditioning (RIC) regimens
were designed to decrease TRM after allogeneic
HSCT but to retain antitumor effects of the allograft
[4,5]. Most prior reports of RIC in FL are small retro-
spective series or subsets of larger series that included
different types of NHL [6-8]. The current study exam-
ined 208 HSCTs for FL between 1997 and 2002 and
compared outcomes after myeloablative conditioning
and RIC.
PATIENTS AND METHODS
Data Sources
The Center for International Blood and Marrow
Transplant Research (CIBMTR) is a voluntary group
of .500 transplant centers worldwide. Participating
centers register basic information on all consecutive
HSCTs to a Statistical Center at the Medical College
of Wisconsin. Detailed demographic and clinical data
are collected on a representative sample of registered
patients using a weighted randomization scheme.
Compliance is monitored by on-site audits. Patients
are followed longitudinally, with yearly follow-up.
Computerized checks for errors, physician reviews of
submitted data, and on-site audits of participating
centers ensure the quality of data.
Patients
The initial study population included all persons
with follicular NHL receiving an HSCT from an
HLA-identical sibling reported to the CIBMTR be-
tween 1997 and 2002. Recipients of unrelated donor
transplants and or in vitro T cell-depleted (TCD)
grafts were excluded.
Definitions of RIC and Myeloablative Conditioning
Regimens
The degree of myelosuppression after RIC is not
entirely predictable, and cannot reliably be used as
a feature to discriminate RIC from conventional mye-
loablative conditioning because rare cases of irrevers-
ible myelosuppression have been reported after
‘‘nonmyeloablative regimens’’ [9] and spontaneous
hematopoietic recovery is sometimes observed after
administration of ‘‘myeloablative’’ doses of total-
body irradiation (TBI) [10,11]. RIC regimens also
have varying levels of organ toxicity. For example,
the commonly used fludarabine-melphalan RIC regi-
men has considerable extramedullary toxicity, and
can cause irreversible myelosuppression [12].
In the absence of a robust biologic classification,
the Regimen-Related Toxicity Working Committee
of the CIBMTR developed the following working
criteria to define RIC: TBI doses\5 Gy as a single
fraction, busulfan doses \9 mg/kg (oral/i.v. equiva-lent), melphalan doses #150 mg/m2, and fludarabine-
based regimens without myeloablative doses of TBI,
busulfan, or melphalan. Myeloablative conditioning
regimens were defined as: TBI with 1 fraction of $5
Gy or fractionated doses of $8 Gy, busulfan doses
$9 mg/kg, or melphalan doses $150 mg/m2. This
consensus definition reflects the practice of a large seg-
ment of the transplant community and has also been
proposed and used by others [4,13,14].
Study Endpoints
Outcomes included TRM, progression, progres-
sion-free survival (PFS), and overall survival (OS).
TRM was defined as death within 28 days posttrans-
plant or death without lymphoma progression. Pro-
gression was defined as progressive lymphoma
posttransplant ($28 days) or lymphoma recurrence.
It could follow a period of ‘‘stable’’ disease posttrans-
plant, or a partial or complete remission. For PFS, sub-
jects were considered treatment failures at the time of
lymphoma progression or death from any cause. OS
was defined as time from the date of transplant to the
date of death or last contact. Other outcomes analyzed
included acute- and chronic graft-versus-host disease
(aGvHD and cGvHD) and cause of death (COD).
aGVHD was defined and graded using established cri-
teria. cGVHD was defined as the development of any
cGVHD based on clinical criteria. COD was reported
by the individual teams involved in the subject’s care.
Treatment of relapse or progression of lymphoma in-
cluding the use of donor lymphocyte infusions (DLI)
was not analyzed.
Statistical Analysis
Patient-, disease-, and transplant-related variables
for patients receiving RIC and myeloablative trans-
plants were compared using chi-square statistic for cat-
egoric variables and the Kruskal-Wallis test for
continuous variables. Univariate probabilities of devel-
oping aGVHD and cGVHD, TRM, and lymphoma
progression were calculated using cumulative inci-
dence curves to accommodate competing risks [15].
Probabilities of OS and PFS were calculated using Ka-
plan-Meier estimator [16]. Confidence intervals (CI)
were calculated with a log transformation.
To compare the outcomes of TRM, lymphoma
progression, PFS, and OS after RIC and myeloablative
conditioning, Cox proportional hazards models were
used to adjust for potential imbalances in baseline
characteristics between treatment cohorts. A stepwise
forward method was used to identify covariates that
influenced outcomes. Any covariate with a P-value
#.05 was considered significant and was included in
the final model. The proportionality assumption for
Cox regression was tested by adding a time-dependent
covariate for each risk factor and each outcome. A
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point was fit in cases where the proportional hazards
assumption was not met [17]. Final results were ex-
pressed as relative risks (RR) of the event with 95% CIs.
The following variables were considered in model
building: conditioning—RIC versus myeloablative
(main effect), age at transplantation, recipient sex,
Karnufsky Performance Score (KPS) at transplantation,
lymphoma stage at diagnosis, lymphoma histology,
B-symptoms, number(s) of pretransplant chemother-
apy regimens, bone marrow involvement, lymphoma
response to chemotherapy at transplantation, disease
state, and sensitivity to chemotherapy at transplant;
CMV—state of recipient and donor, use of pretrans-
plant rituximab, time from diagnosis to HSCT and
donor-recipient sex match. Type of conditioning reg-
imen (RIC versus myeloablative) was retained in all
steps of model building because it was the main effect
of interest. No interactions were detected between the
main effect and all significant risk factors tested. The
final multivariate analyses reported are based on out-
comes censored at 3 years to balance the difference
in length of follow-up between the cohorts. Analyses
were performed using SAS software, version 8.2 (SAS
Institute, Cary, NC). The study had 80% power to
detect statistically significant difference of 20% in
OS between the cohorts.
RESULTS
Patient, Disease-, and Transplant-Related
Variables
One hundred twenty subjects received myeloablative
conditioning and 88 received RIC (Table 1). Complete-
ness of follow-up (the ratio of the sum of the observed
follow-up time to the sum of the potential follow-up
time for all subjects [18]) was 90% for both cohorts.
Table 1. Preparative Regimens—Conventional Myeloablative versus
Reduced Intensity
Preparative Regimens N N (%) N N (%)
Conventional myeloablative 120
CY 1 TBI (TBI dose .500 cGy) 80 (67) —
BU 1 CY 30 (25) —
TBI dose $500 cGy 10 (8) —
Reduced-intensity conditioning 88
Fludarabine 1 MEL ± ATG — 16 (18)
Fludarabine 1 BU
(dose\9 mg/kg) ± ATG
— 22 (25)
Fludarabine 1 TBI — 9 (10)
Fludarabine 1 CY — 37 (42)
Fludarabine ± other* — 3 (4)
TBI 5 300 cGy — 1 (1)
Cy indicates cyclophoshamide; TBI, total-body irradiation; Bu, bu-
sulfan; Mel, Melphalan; VP16, Etoposide; Ara-C, Cytarabine;
ATG, antithymocyte globulin.
1. Fludarabine 1 Campath (n 5 1).
2. Fludarabine 1 Ara-C (n 5 2).
*Others include (n 5 3).Table 2 describes subject-, disease-, and trans-
plant-related variables of the cohorts. The proportion
of RIC transplants was\10% in 1997, and steadily in-
creased, reaching.80% by 2002. Median follow-up of
survivors of myeloablative transplants was 50 months
(range: 4-96 months) and 35 months (4-82 months; P
5 .001) in the RIC cohort. Median age at transplant
was 44 years (range: 27-70 years) in the myeloablative
cohort compared to 51 years (27-70 years) in the RIC
cohort (P\ .001). Pretransplant KPS did not differ
significantly between the cohorts.
Lymphoma-stage at diagnosis was similar between
the cohorts;.80% were equal to or greater than stage
3. Distribution of subjects was similar across the 3 his-
tologic grades of FL. Although the RIC cohort had
a higher proportion of subjects at or beyond second
complete remission (CR2 and subsequent relapses or
remissions; 21% versus 48%: P 5 .01), there was
a higher proportion of patients with primary induction
failure in the myeloablative group (36% versus 26%;
P5 .01). Time from diagnosis to transplant was a me-
dian of 25 months (3-198 months) in the myeloablative
versus 36 months (6-195 months) in the RIC cohort
(P5 .002). There was a higher incidence of bone mar-
row involvement in the myeloablative cohort (59%
versus 43%, P 5 .03). Few subjects in either cohort
(6% in myeloablative and 10% in RIC; P 5 .24) had
prior autotransplants. Subjects receiving an RIC trans-
plant were more likely to have received rituximab pre-
transplant (26% in myeloablative versus 45%,P5 .003).
Conditioning Regimens
Among myeloablative regimen recipients, cyclo-
phosphamide (Cy) and TBI (Cy-TBI) and busulfan
(Bu) and Cy (BU-Cy) accounted for 92% of condition-
ing regimens; others are summarized in Table 1. The
most common RIC conditioning regimens were flu-
darabine (Flu) and Cy (42%), Flu and Bu (25%), Flu
and melphalan (Mel; 18%), and Flu with TBI (10%).
Other RIC regimens are summarized in Table 1.
GVHD prophylaxis schemes varied between cohorts.
Seventy-nine percent of subjects in the myeloablative
cohort received a calcineurin inhibitor with metho-
trexate (MTX); this was used in only 48% of RIC
recipients (P 5 .001).
Outcomes
The variables considered in model building are
summarized in Table 3. Outcomes are summarized
in Table 4.
GVHD
Cumulative incidences of aGVHD equal to or
greater than grade 2 by day 100 were 36% (28-45) in
the myeloablative cohort and 44% (34-55) in the
RIC cohort (P5 .26). Incidence of cGVHD at 3 years
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Myeloablative RIC
Variable N N (%) N N (%) P-value
Number of patients 120 88
Age, median (range), years 120 44 (27-70) 88 51 (27-70) \.001
Age at transplant, years 120 88 \.001
21-30 6 (5) 3 (3)
31-40 36 (30) 11 (13)
41-50 60 (50) 30 (34)
51-60 17 (14) 37 (42)
$61 1 (1) 7 (8)
Male sex 120 68 (57) 88 46 (52) .53
Karnofsky score pretransplant 119 86 .49
\90 40 (34) 25 (29)
$90 79 (66) 61 (71)
Disease stage at diagnosis 115 85 .10
I 2 (2) 7 (7)
II 11 (9) 9 (11)
III 30 (26) 26 (31)
IV 72 (63) 43 (51)
Disease related
Histology 120 88 .09
Small cleaved 59 (49) 35 (40)
Mixed small and large cell 49 (41) 35 (40)
Predominantly large cell 12 (10) 18 (20)
B-symptoms at diagnosis 112 30 (27) 75 23 (31) .56
Number of prior chemotherapy regimens 118 85 .28
1 19 (16) 9 (11)
2 38 (32) 21 (25)
3 23 (20) 18 (21)
41 38 (32) 37 (43)
Disease status at transplant 79 77 0.01
Primary Induction Failure 28 (36) 20 (26)
CR1 6 (8) 2 (3)
REL1 28 (35) 18 (23)
CR21 9 (11) 17 (22)
REL21 8 (10) 20 (26)
Bone marrow involvement 108 79 0.028
Yes 64 (59) 34 (43)
No 44 (41) 45 (57)
Chemosensitivity disease at transplant 118 86 0.74
Sensitive 85 (72) 58 (68)
Resistant 27 (23) 23 (26)
Untreated/Unknown 6 (5) 5 (6)
Coexisting disease at transplant 118 86 .15
Yes 39 (33) 37 (43)
Fungal infection at transplant 118 87 .11
Yes 2 (2) 5 (6)
Serum creatinine at transplant median
(range), mg/dL
118 0.9 (0-1.8) 88 0.9 (0-1.9) .15
Transplant related
Previous autologous transplant 120 7 (6) 88 9 (10) .24
Time from autologous to allogeneic
transplant, median (range), months
6 16 (10-50) 9 26 (12-60) .29
Donor/recipient CMV status 117 83 .16
1/1 39 (33) 41 (49)
1/2 17 (15) 9 (11)
2/1 23 (20) 12 (15)
2/2 38 (32) 21 (25)
Time from diagnosis to transplant,
median (range), months
120 25 (3-198) 88 36 (6-195) .002
Time from diagnosis to transplant,
months
120 88 .002
\12 months 22 (18) 9 (10)
(Continued )
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Myeloablative RIC
Variable N N (%) N N (%) P-value
12-24 months 37 (31) 13 (15)
.24 months 61 (51) 66 (75)
Rituximab pretransplant 120 31 (26) 88 40 (45) .003
Donor-recipient sex match 118 88 .83
M-M 39 (33) 24 (27)
M-F 27 (23) 21 (24)
F-M 28 (24) 22 (25)
F-F 24 (20) 21 (24)
Source of stem cells 120 88 \0.001
BM 44 (37) 8 (9)
PBSC 76 (63) 80 (91)
Year of transplant 120 88 \0.001
1997 35 (29) 2 (2)
1998 21 (17) 5 (6)
1999 32 (27) 8 (9)
2000 14 (12) 17 (19)
2001 11 (9) 24 (27)
2002 7 (6) 32 (36)
GVHD prophylaxis 116 87 \.001
FK506/CsA 1 MTX 99 (85) 43 (49)
FK506/CsA without MTX ± others 17 (15) 44 (51)
Radiation posttransplant 119 87 .39
Yes 1 (1) 3 (4)
No 2 (2) 1 (1)
No posttransplant therapy given 116 (97) 83 (95)
DLI posttransplant 120 88 .82
Yes 1 (1) 1 (1)
No 119 (99) 87 (99)
Median hospital stay, days* 95 28 (6-100) 71 26 (2-100) .17
Median follow-up of survivors, months 82 50 (4-96) 54 35 (4-82) \.001
CR indicates complete response; REL, relapse; CMV, cytomegalovirus; BM, bone marrow; PBSC, peripheral blood stem cell; GVHD, graft-
versus-host disease; FK506, tacrolimus; CsA, cyclosporine; MTX, methotrexate; DLI, donor leukocyte infusion.
*In patients who survive .100 days.was 46% (36-52) in the myeloablative cohort and 62%
(52-72; P 5 .03) in the RIC cohort (Table 4).
TRM
Day-30, day-100, 1-year, and 3-year mortality rates
were similar between the cohorts (Table 4). Cumula-
tive incidence estimates of TRM at 1 year were 23%
in both cohorts. In multivariate analyses, the type of
conditioning did not correlate significantly with
TRM (RR for RIC 5 1.10; 95% CI 5 0.64-1.91, P 5
.72; Tables 4 and 5, and Figure 1). A lower performance
score, KPS\90% (RR 5 2.20, 95% CI 5 1.27, 3.82,
P 5 .005) and chemotherapy-resistant lymphoma
(RR5 1.94, 95% CI5 1.12, 3.37, P5 .019) were asso-
ciated with higher TRM. None of the imbalances
between the cohorts (age, disease stage, interval from
diagnosis to transplant, bone marrow involvement, or
prior rituximab) were associated with TRM.
Progression
The 3-year univariate probabilities of progression
were 8% (4%-14%) in the myeloablative versus 17%
(10%-26%) in the RIC cohort. In multivariate analy-ses, there was a statistically significant higher risk of
progression with RIC (RR 5 2.97, 95% CI 5 1.03-
8.55, P5 .044; Tables 4 and 5 and Figure 2). No other
variables were associated with TRM.
PFS and Treatment Failure
The 3-year univariate probabilities of PFS were
67% (58%-75%) in the myeloablative and 55%
(44%-65%) in the RIC cohort (P 5 .07; Table 4).
This difference was not significant in multivariate
analyses (RR of treatment failure in RIC cohort 5
1.38, 95% CI 5 0.85-2.21, P 5 .19; Table 5 and
Figure 3). A KPS\90 (RR 5 1.89, 95% CI 5 1.16-
3.06, P 5 .01) and chemotherapy-resistant lymphoma
(RR 5 1.96, 95% CI 5 1.21, 3.18, P 5 .006) were
strongly associated with lower PFS. None of the vari-
ables that were imbalanced between the cohorts were
associated with PFS.
Survival and Mortality
The 3-year univariate probability of survival was
71% (63%-79%) in the myeloablative versus 62%
(51%-72%) in the RIC cohort (P 0.15; Table 4).
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with survival in the multivariate model (RR of mortal-
ity for RIC5 1.24, 95% CI5 0.76-2.02,P 0.39; Table 5
and Figure 4). In multivariate analyses, a KPS \90
(RR 5 2.04, 95% CI 5 1.25-3.35, P 5 .005) and che-
motherapy-resistant lymphoma (RR 5 1.95, 95% CI
5 1.19-3.20, P 5 .008) were associated with more
deaths. None of the variables that were imbalanced be-
tween the cohorts were associated with OS.
Statistical models were constructed to adjust for
potential time-varying effect of RIC versus myeloabla-
tive transplants. There was no difference in OS and
PFS within 9 months, and RIC had worse OS and
PFS probabilities after 9 months of transplantation.
A Cox model [19] stratified on treatment groups, did
not show a significant difference in OS or PFS between
the 2 treatment groups at fixed late time points.
Causes of Death
There were 38 deaths in the myeloablative cohort
and 34 in the RIC cohort. Seven deaths in the myeloa-
blative cohort and 9 deaths in the RIC cohort were at-
tributed to progressive lymphoma. Other causes of
death are summarized in Table 6.
Hospital Stay of Survivors
The median hospital stay of recipients who sur-
vived .100 days after myeloablative conditioning
and RIC were similar at 28 days (6-100) and 26
(2-100) days, respectively.
Table 3.Variables Tested in Cox Proportional Hazards RegressionModels
Main effect variable*
Conditioning regimen: myeloablative versus RIC
Patient-related variables:
Age at transplant: 21-30 versus 31-40 versus 41-50 versus 51-60
versus $61 years
Sex: female versus male
Karnofsky performance status at transplant: $90% versus\90%
Disease stage at diagnosis: I/II versus III/IV
Disease-related:
Histology: small cleaved versus others
B-symptoms at diagnosis: yes versus no
Number of prior chemotherapy regimens: #2 versus .2
Bone marrow involvement: yes versus no
Chemosensitivity of disease at transplant: sensitive versus others
Disease status and chemosensitivity at transplant:
Sensitive CR versus sensitive relapse versus PIF-sensitive versus
PIF-resistant versus resistant relapse versus unknown
Treatment-related:
Donor/recipient CMV status: 1/1 vs 1/2 vs 2/1 vs 2/2 vs not
tested/inconclusive
Time from diagnosis to transplant:\12 versus 12-24 versus .24
months
Rituximab pretransplant: yes versus no
Donor-recipient sex match: M-M versus M-F versus F-M versus F-F
*Included in all models.DISCUSSION
The initial studies of allogeneic transplantation in
FL and an analysis of 113 patients reported to the
International Bone Marrow Transplant Registry
(IBMTR) transplanted between 1984 and 1995
showed low rates of disease recurrence but a TRM
up to 40% [2,20]. Poor performance status at trans-
plantation, chemotherapy refractory disease, and age
.40 were predictors of worse outcome. The RIC
approach was developed with the intent of further
reducing the TRM associated with allogeneic trans-
plantation, whereas preserving graft-versus-lymphoma
(GVL) effects and is increasingly used as an alter-
native to myeloablative transplantation. Excellent
results were reported after RIC in low-grade lym-
phoma with chemotherapy-sensitive disease [6,8,21-23].
However, high TRM as well as increased relapse risk
have been suggested in recent studies [24,25].
Our analysis shows that the practice of allogeneic
transplantation in FL has shifted in favor of RIC
conditioning, which by 2002 represented 80% of
Table 4. Univariate Probabilities of Transplant Outcomes
Myeloablative RIC
Outcome event N
Prob
(95% CI) N
Prob
(95% CI) P-Value*
30-day mortality 120 8 (4-14) 88 5 (1-10) .26
100-day mortality 120 18 (12-26) 88 14 (7-22) .36
ANC .0.5  109/L 117 83
@ 28 days 97 (94-99) 100 (0-100) .07
@ 100 days 98 (95-100) 100 (0-100) .13
Acute GVHD @ 100
days, grades (2-4)
115 36 (28-45) 87 44 (34-55) .26
Acute GVHD @ 100
days, grades (3-4)
115 13 (7-20) 87 21 (13-30) .13
Chronic GVHD 118 86
@ 1 year 44 (34-53) 58 (47-68) .06
@ 3 years 46 (36-56) 62 (51-72) .03
TRM 120 88
@ 1 year 23 (16-31) 23 (15-32) .97
@ 3 years 25 (17-33) 28 (19-38) .60
Progression/relapse 120 88
@ 1 year 7 (4-13) 15 (8-23) .11
@ 3 years 8 (4-14) 17 (10-26) .06
PFS 120 88
@ 1 year 70 (61-78) 62 (52-72) .26
@ 3 years 67 (58-75) 55 (44-65) .07
Overall survival 120 88
@ 1 year 74 (66-81) 69 (59-78) .44
@ 3 years 71 (63-79) 62 (51-72) .15
ANC indicates absolute neutrophil recovery; TRM, treatment-
related mortality; PFS, progression-free survival; PROB, proba-
bility; CI, confidence interval; OS, overall survival.
*30-day mortality and 100-day mortality were tested using the chi-
square test. Probabilities of neutrophil recovery, aGVHD, cGVHD,
TRM, and progression/relapse were calculated using the cumulative
incidence estimate. PFS and OS were calculated using the Kaplan-
Meier product limit estimate.
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ferences in stem cell source and GVHD prophylaxis
regimens between those receiving myeloablative and
RIC conditioning. For RIC transplants peripheral
blood stem cell grafts were almost exclusively used,
and GVHD prophylaxis commonly did not include
MTX. These aspects of treatment are typical of the
RIC conditioning approach, and their effect on out-
come cannot be separated from that of the choice of
conditioning method. As in other comparative studies
[25] of RIC and myeloablative conditioning, these
Table 5.Multivariate Analysis of Treatment-Related Mortality, Relapse/
Progression, Progression-Free Survival, and Overall Survival
Variables: N
Relative Risk
(95% CI) P-Value
Treatment-related mortality
Main effect
Myeloablative 120 1.00
RIC 88 1.10 (0.64-1.91) .72
Other significant covariates
Karnofsky performance
status at transplant
$90% 140 1.00
\90% 65 2.20 (1.27-3.82) .005
Chemosensitivity of disease
at transplant
Sensitive 143 1.00
Others 61 1.94 (1.12-3.37) .019
Relapse/progression
Main effect
Myeloablative 120 1.00
RIC 88 2.97 (1.03-8.55) .044
Progression-free survival
Main effect:
(risk of treatment failure)
Myeloablative 117 1.00
RIC 84 1.38 (0.85-2.21) .19
Other significant covariates:
Karnofsky performance
status at transplant
$90% 137 1.00
\90% 64 1.89 (1.16-3.06) .010
Chemosensitivity of disease
at transplant
Sensitive 141 1.00
Others 60 1.96 (1.21-3.18) .006
Overall survival:
Main effect:
(risk of mortality)
Myeloablative 117 1.00
RIC 84 1.24 (0.76-2.02) .39
Other significant covariates:
Karnofsky performance
status at transplant
$90% 137 1.00
\90% 84 2.04 (1.25-3.35) .005
Chemosensitivity of disease
at transplant
Sensitive 141 1.00
Others 60 1.95 (1.19-3.20) .008
CI indicates confidence interval.differences do not preclude a comparison of the condi-
tioning modalities.
There were several differences in the patient char-
acteristics. Those undergoing RIC were on average
older, but very few patients in either cohort were below
40, the age cutoff under which we previously have
demonstrated a superior outcome [3]. RIC transplant
recipients also had a longer delay between diagnosis
and transplant, more often were in second or subse-
quent remission, and had more frequently received rit-
uxan prior to transplant. Those undergoing
myeloablative conditioning had more commonly pri-
mary refractory disease and more frequently bone
marrow involvement at the time of transplant. None
of these features had prognostic significance in multi-
variate analysis. The groups were well balanced for
performance status and chemotherapy sensitivity of
lymphoma, the 2 most consistent prognostic features
in our previous analyses and confirmed again in the
current study.
We found that RIC and myeloablative transplanta-
tion for FL had very similar TRM. These results are
consistent with other recently published comparisons
of RIC and myeloablative regimens in FL, NHL,
and Hodgkin lymphoma [24-26], but are in apparent
contrast with data from the Seattle group, who found
Figure 1.Cumulative incidence of TRM after allogeneic transplants
for FL by conditioning regimen—conventional myeloablative versus
RIC.
Figure 2. Cumulative incidence of progression/relapse after alloge-
neic transplants for FL by conditioning regimen—conventional
myeloablative versus RIC.
Nonmyeloablative Transplantation in Follicular NHL 243that TRM was reduced in patients receiving the RIC
regimen of fludarabine and low-dose TBI [23,27].
The risk of aGVHD was similar across the 2 groups,
but there was an increased risk of cGVHD at 3 years
in the RIC group. This may be related to the differ-
ences in GVHD prophylaxis regimens as well as the
greater use of peripheral blood stem cells (PBSC)
grafts in patients receiving RIC [28,29].
In multivariate analysis there was an increased risk
of lymphoma progression after RIC compared to mye-
loablative conditioning. No other patient, disease, or
transplant-related factor that we examined was signif-
icantly associated with risk of progression. Despite the
increased risk of relapse after RIC, there were no
significant differences in OS or PFS between the 2
cohorts.
The equivalence of RIC and myeloablative regi-
mens contrasts with recent single institution reports
and has several possible explanations. One is that out-
comes after myeloablative transplants have improved
over the past decade and comparison of RIC with his-
toric myeloablative transplant data is no longer appro-
priate. An IBMTR analysis of FLs undergoing
myeloablative transplants between 1990 and 2000
found that TRM had steadily declined in later years,
with a survival of 75% at 2 years for patients undergo-
Figure 3.Adjusted probability of PFS after allogeneic transplants for
FL by conditioning regimen—conventional myeloablative versus
RIC.
Figure 4. Adjusted probability of OS after allogeneic transplants for
FL by conditioning regimen—conventional myeloablative versus
RIC.ing myeloablative HSCT for FL between 1997 and
1999 [3]. It is also possible that the decision to use
RIC may have involved pretransplant variables un-
known to us for which we could therefore not adjust.
However, within the limits of a retrospective study,
we could not detect any difference in PS, comorbid-
ities, or frequency of prior infections between the 2
groups. Because the overall annual number of trans-
plants for FL was unchanged over the interval we stud-
ied, it is likely that the observed shift to RIC
transplants represents a change in practice pattern as
opposed to increased access to allogeneic transplanta-
tion for patients with lower PS. The lack of difference
in survival between myeloablative and RIC cohorts
could also arise from the diversity of RIC conditioning
regimens. Specific RIC conditioning regimens may
have different safety and efficacy profiles, but individ-
ual regimens could not be further analyzed because
there were too few subjects in each subgroup.
Our analysis did not have the ability to evaluate
costs or nonfatal toxicity such as mucositis, but 1 im-
portant parameter, the median duration of hospitaliza-
tion of survivors, was not different between the groups.
We were also unable to analyze the quality of life im-
pact of conditioning regimen intensity. Although
such additional benefits may exist, the higher risk of
late progression in RIC without a demonstrable bene-
fit in decreasing TRM is of concern, particularly be-
cause the median follow-up in the RIC cohort was
shorter. Higher relapse/progression risk after RIC
compared to myeloablative regimens has also recently
been reported in other analyses of RIC in NHL [25]
(40% with low-grade NHL), CLL [30], and multiple
myeloma [14].
Importantly, these data demonstrate that regard-
less of conditioning intensity, allogeneic HSCT re-
mains an effective treatment modality in patients
with advanced FL with excellent 3-year DFS rates of
55% to 67%. Although it is disappointing that RIC
Table 6. Causes of Death for Patients Who Received Allogeneic Matched
Sibling Donor Transplants for Follicular Lymphoma
Myeloablative RIC
Causes of death
N
eval N (%)
N
eval N (%)
Number of patients 38 34
Primary disease 7 (18) 9 (26)
GVHD 4 (11) 6 (18)
Pulmonary 2 (5) 3 (9)
Infection 8 (21) 7 (20)
Organ failure 11 (29) 4 (12)
New malignancy 0 1 (3)
Other
(hemorrhage/vascular/unknown)
6 (16) 4 (2)
GVHD indicates graft-versus-host disease; RIC, reduced-intensity
conditioning.
244 P. Hari et al.did not lead to significant benefits in terms of reduced
TRM or improved survival for follicular NHL, this
approach has gained rapid acceptance in practice in
recent years. The overall therapeutic equivalence,
presumed quality-of-life benefits, and tolerability of
RIC in older patients with more advanced disease are
driving practice patterns. However, in view of the in-
creased risk of progression that we observed, further
validation is recommended in a larger dataset with
longer follow-up as well as quantification of potential
nonlethal toxicity and quality-of-life benefits. Certain
RIC regimens and or GVHD prophylaxis schemes
may ultimately prove to be more successful than
others, and should be tested further in hypothesis-
driven prospective trials.
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